Modality
Radioligand
MOA
BCL-2i
Target
SOS1
Pathway
DDR
PsoriasisOCDCF
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
Feb 2021
→ Dec 2029
Phase 1Current
NCT06793208
2,152 pts·OCD
2021-02→2029-12·Terminated
2,152 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-183.7y awayInterim· OCD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Termina…
Catalysts
Interim
2029-12-18 · 3.7y away
OCD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06793208 | Phase 1 | OCD | Terminated | 2152 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |